-
1 Comment
Eisai Co., Ltd is currently in a long term uptrend where the price is trading 46.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Eisai Co., Ltd's total revenue sank by 3.0% to $181B since the same quarter in the previous year.
Its net income has dropped by 58.1% to $19B since the same quarter in the previous year.
Finally, its free cash flow fell by 87.0% to $2B since the same quarter in the previous year.
Based on the above factors, Eisai Co., Ltd gets an overall score of 2/5.
| ISIN | JP3160400002 |
|---|---|
| Sector | Healthcare |
| Exchange | F |
| CurrencyCode | EUR |
| Industry | Drug Manufacturers - Specialty & Generic |
| Target Price | None |
|---|---|
| Dividend Yield | 3.9% |
| Beta | -0.16 |
| Market Cap | 7B |
| PE Ratio | 20.22 |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for EII.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
